Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Falls 3.02% Today

Glenmark Pharmaceuticals Ltd. Share Price experienced a notable decline today, falling by 3.02% to close at Rs 2,193.75. This movement comes as part of a broader market trend impacting the healthcare sector. With a market capitalisation of Rs 61,658.05 crore, Glenmark Pharmaceuticals Ltd. is classified as a Large Cap company. Today's price action highlights the volatility in the market, as the stock opened at Rs 2,266.60, reached a high of Rs 2,268.80, and a low of Rs 2,193.00. The turnover for the day was Rs 2.64 crore, with a total volume of 312,858 shares traded across BSE and NSE.

The decline in Glenmark Pharmaceuticals Ltd. Share Price reflects the broader fluctuations within the healthcare sector, which have been contributing to today's price movement. While the data confirms the price fall, no specific company-related catalyst has been identified.

Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,193.75
Previous Close	Rs 2,261.95
Today's Change	Rs -68.2 (-3.02%)
Day Open	Rs 2,266.6
Day High	Rs 2,268.8
Day Low	Rs 2,193
Current Volume (BSE)	12,049
BSE Traded Volume	12,049
NSE Traded Volume	3,00,809
Combined NSE + BSE Volume	3,12,858
Turnover	Rs 2.64 crore
Market Capitalisation	Rs 61,658.05 crore
Market Cap Category	Large Cap

Glenmark Pharmaceuticals Ltd. (GLENMARK) traded at Rs 2,193.75. versus the previous close of Rs 2,261.95, a fall of 3.02%. The stock opened at Rs 2,266.6, reached Rs 2,268.8, touched Rs 2,193. Reported volume was 12,049.

Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 61,658.05 crore

Glenmark Pharmaceuticals Ltd. operates within the healthcare sector, with a market capitalisation of Rs 61,658.05 crore. The company's valuation metrics, such as P/E and P/B ratios, provide insights into its market standing relative to peers and sector benchmarks.

The healthcare sector's benchmark data reveals a median P/E of 26.56 and a median P/B of 1.91, which serve as reference points for evaluating Glenmark's valuation. The sector's ROE and ROCE medians are 10.74% and 13.24%, respectively, indicating the average profitability and efficiency within the industry.

Glenmark Pharmaceuticals Ltd.'s market position within the healthcare sector is significant, given its large market capitalisation. The company's performance and valuation metrics should be assessed in the context of sector trends and peer performance to gauge its competitive standing and potential for growth.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Benchmark Median P/E	26.56x
Benchmark Average P/E	87.07x
Benchmark P/E Range	3.47x to 3,385.56x
Benchmark Median P/B	1.91x
Benchmark Median ROE	10.74%
Benchmark Median ROCE	13.24%
Company Market Capitalisation	Rs 61,658.05 crore
Benchmark Median Market Cap	Rs 138.42 crore

Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

The healthcare sector, encompassing 198 companies, provides a broad benchmark for evaluating Glenmark Pharmaceuticals Ltd.'s performance. The sector's median P/E of 26.56 and median P/B of 1.91 offer a baseline for assessing Glenmark's valuation. The sector's ROE and ROCE medians, at 10.74% and 13.24% respectively, highlight the average profitability and capital efficiency within the industry.

Glenmark Pharmaceuticals Ltd.'s market capitalisation of Rs 61,658.05 crore positions it significantly above the sector's median of Rs 138.42 crore, reflecting its substantial market presence. The company's performance should be evaluated against sector trends and peer metrics to understand its competitive positioning and growth potential.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,856.59	30.28	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,686.76	40.11	8.17	28.21	26.35
Hikal Ltd.	HIKAL	2,676.24	0	2.27	15.22	16.15
Panacea Biotec Ltd.	PANACEABIO	2,540.37	0	3.11	0	5.36
Solara Active Pharma Sciences Ltd.	SOLARA	2,446.19	0	1.91	17.23	15.34

Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 61,658.05 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

In the healthcare sector, Glenmark Pharmaceuticals Ltd. competes with several peers, including Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Hikal Ltd. These companies vary in market capitalisation, P/E, P/B, ROE, and ROCE metrics, providing a comparative framework for Glenmark's performance.

Dishman Carbogen Amcis Ltd. has a market cap of Rs 2,856.59 crore, with a P/E of 30.28 and a P/B of 0.44. Kwality Pharmaceuticals Ltd. boasts a higher ROE of 28.21% and a market cap of Rs 2,686.76 crore. These comparisons highlight Glenmark's relative market position and valuation within the sector.

Why Investors Are Watching Glenmark Pharmaceuticals Ltd.

Investors are closely monitoring Glenmark Pharmaceuticals Ltd. due to its recent price action and sector positioning. The company's market capitalisation and sector dynamics make it a focal point for healthcare sector analysis.

• Price Action: A 3.02% decline today, marking a significant market movement.
• Technical Position: Notable trading volume and price fluctuation.
• Fundamental Context: Large market cap with sector benchmark comparisons.
• Sector Positioning: Significant presence in the healthcare sector.

Investors should continue to monitor Glenmark Pharmaceuticals Ltd.'s performance, considering both market trends and sector-specific developments that may impact its future trajectory.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. is a prominent player in the healthcare sector, focusing on the development and commercialization of pharmaceutical products. The company operates across various segments, including branded generics, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). Glenmark's diverse product portfolio and strategic market presence position it as a key competitor in the industry.

The company's operations span multiple geographies, with a strong emphasis on research and development to drive innovation and growth. Glenmark's commitment to quality and regulatory compliance underpins its reputation in the global pharmaceutical market.

Track Glenmark Pharmaceuticals Ltd. Share Price on Univest

Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors can track Glenmark Pharmaceuticals Ltd. Share Price on Univest for real-time updates and insights. Univest provides comprehensive data on technical indicators, fundamental ratios, shareholding patterns, and market trends, enabling informed investment decisions.

Frequently Asked Questions

What caused Glenmark Pharmaceuticals Ltd. Share Price to fall today?

Ans. Glenmark Pharmaceuticals Ltd. Share Price fell 3.02% today, reflecting broader market trends in the healthcare sector. No specific company-related catalyst has been identified for this decline. The stock moved -3.02% during the session.

What is the sector benchmark for P/E in the healthcare industry?

Ans. The sector benchmark for P/E in the healthcare industry is a median of 26.56, providing a reference point for evaluating company valuations. The relevant peer median P/E is 26.56x. The peer average P/E is 87.07x.

How does Glenmark Pharmaceuticals Ltd.'s market cap compare to its peers?

Ans. Glenmark Pharmaceuticals Ltd.'s market cap of Rs 61,658.05 crore is significantly higher than its peers, such as Dishman Carbogen Amcis Ltd. with Rs 2,856.59 crore. The company operates in the Healthcare sector.

What is the significance of today's price action for Glenmark Pharmaceuticals Ltd.?

Ans. Today's price action, with a 3.02% decline, highlights market volatility and sector-specific dynamics impacting Glenmark Pharmaceuticals Ltd. The stock moved -3.02% during the session. The intraday range extended from Rs 2,193 to Rs 2,268.8.

What are the key valuation metrics for the healthcare sector?

Ans. Key valuation metrics for the healthcare sector include a median P/E of 26.56 and a median P/B of 1.91, indicating average valuations. The relevant peer median P/E is 26.56x. The peer average P/E is 87.07x.